Patients
Trials
Expanded Access
Pipeline
Zanidatamab
ZW49
Preclinical & Advanced Discovery
Partnerships
Publications
Partners
Technology
Azymetric™
ZymeLink™
EFECT™
ProTECT™
Science
Careers
Apply
Perks & Benefits
Corporate Gallery
About
Leadership
Board of Directors
News
Investors & Media
News
Zanidatamab Phase 2 Clinical Trial Demonstrates Promising Response Rate And Durability In First-Line HER2-Positive Gastroesophageal Adenocarcinoma (GEA) At The European Society For Medical Oncology (ESMO) Annual Congress
Sep 16, 2021
Back